Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline

Am J Gastroenterol. 2022 Apr 1;117(4):559-587. doi: 10.14309/ajg.0000000000001680.


Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.

MeSH terms

  • Adenocarcinoma* / diagnosis
  • Adenocarcinoma* / epidemiology
  • Adenocarcinoma* / therapy
  • Barrett Esophagus* / complications
  • Barrett Esophagus* / diagnosis
  • Barrett Esophagus* / therapy
  • Esophageal Neoplasms* / diagnosis
  • Esophageal Neoplasms* / etiology
  • Esophageal Neoplasms* / therapy
  • Esophagoscopy
  • Gastroesophageal Reflux* / complications
  • Humans